Experienced in Metabolic Syndrome

Takeshi Osonoi

Naka, JP 
Experienced in Metabolic Syndrome
Naka, JP 
OverviewLocationsClinical Research

Overview

Takeshi Osonoi practices in Naka, Japan. Mr. Osonoi is rated as an Experienced expert by MediFind in the treatment of Metabolic Syndrome. His top areas of expertise are Type 2 Diabetes (T2D), Diabetic Nephropathy, Low Blood Sugar, and Atherosclerosis.

His clinical research consists of co-authoring 73 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Metabolic Syndrome.

Gender
Male

Locations

Naka, Japan
Other Locations
Japan
Naka, Japan
Ibaraki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Drug
Study Drugs: Dulaglutide, Biguanide (BG), Sulfonylurea (SU), Alpha-Glucosidase Inhibitors (?-GI), Thiazolidinedione (TZD), Glinides (GLN), Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i)
Study Phase: Phase 3
A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: April 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

73 Total Publications

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Osonoi's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile